The expression of epidermal growth factor receptor and Ki67 in primary and relapse nasopharyngeal cancer: a micro-evidence for anti-EGFR targeted maintenance therapy

[1]  D. Heron,et al.  Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  G. Capellá,et al.  Cetuximab may inhibit tumor growth and angiogenesis induced by ionizing radiation: a preclinical rationale for maintenance treatment after radiotherapy. , 2010, The oncologist.

[3]  T. Björk-Eriksson,et al.  Expression modes and clinical manifestations of latent membrane protein 1, Ki‐67, cyclin‐B1, and epidermal growth factor receptor in nonendemic nasopharyngeal carcinoma , 2009, Head & neck.

[4]  Jinming Yu,et al.  The Prognostic Value of 18F-Fluorodeoxyglucose Uptake by Using Serial Positron Emission Tomography and Computed Tomography in Patients With Stage III Nonsmall Cell Lung Cancer , 2008, American journal of clinical oncology.

[5]  C. Bokemeyer,et al.  Platinum-based chemotherapy plus cetuximab in head and neck cancer. , 2008, The New England journal of medicine.

[6]  J. Rich,et al.  Cancer stem cells in radiation resistance. , 2007, Cancer research.

[7]  G. Scagliotti,et al.  Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer , 2007, Cancer.

[8]  K. Ang,et al.  Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation. , 2007, International journal of radiation oncology, biology, physics.

[9]  Christopher U. Jones,et al.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.

[10]  Chong Zhao,et al.  Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Sham,et al.  Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. , 2004, International journal of radiation oncology, biology, physics.

[12]  T. Poon,et al.  Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma—a prospective study , 2003, Head & neck.

[13]  K Kian Ang,et al.  The epidermal growth factor receptor mediates radioresistance. , 2003, International journal of radiation oncology, biology, physics.

[14]  R. Schmidt‐Ullrich.  Molecular targets in radiation oncology , 2003, Oncogene.

[15]  Antony W Burgess,et al.  Epidermal growth factor receptor: mechanisms of activation and signalling. , 2003, Experimental cell research.

[16]  T. Mok,et al.  Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Pignon,et al.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta analysis of chemotherapy on head and neck cancer , 2001 .

[18]  Jun Ma,et al.  Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  F. Caponigro,et al.  Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG). , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  J. Bourhis,et al.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data , 2000, The Lancet.

[21]  R. Weichselbaum,et al.  Blockade of the Vascular Endothelial Growth Factor Stress Response Increases the Antitumor Effects of Ionizing Radiation , 1999 .

[22]  E. Tan,et al.  Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  R. Weichselbaum,et al.  Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. , 1999, Cancer research.

[24]  M. Leblanc,et al.  Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  E. Dmitrovsky,et al.  Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  R. Weichselbaum,et al.  Activation of Src-like p56/p53lyn tyrosine kinase by ionizing radiation. , 1994, The Journal of biological chemistry.

[27]  J. Armand,et al.  Nasopharyngeal cancer: epidemiology, staging, and treatment. , 1994, Seminars in oncology.

[28]  B. Christensson,et al.  Expression of Ki67 antigen, epidermal growth factor receptor and Epstein-Barr virus-encoded latent membrane protein (LMP1) in nasopharyngeal carcinoma. , 1994, European journal of cancer. Part B, Oral oncology.

[29]  Y. F. Poon,et al.  Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. , 1992, International journal of radiation oncology, biology, physics.

[30]  M. Del Vecchio,et al.  Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicenter randomized study. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.